Given that the IFNGrGS characterized an immune-activated phenotype of GBM, we employed two algorithms (TIDE and ImmuneCellAI) to assess the efficacy of the IFNG-associated gene signatures in predicting ICB responsiveness in GBM and compared the predicted results using SubMap (52–54). This evidence concerns the gene IFNG and glioblastoma.